BSF Enterprise (BSFA) Competitors

GBX 4.63
-0.12 (-2.57%)
(As of 03:22 AM ET)

BSFA vs. APTA, ROQ, IXI, EVG, FAB, VAL, GENF, OCTP, PYC, and NFX

Should you be buying BSF Enterprise stock or one of its competitors? The main competitors of BSF Enterprise include Aptamer Group (APTA), Roquefort Therapeutics (ROQ), IXICO (IXI), Evgen Pharma (EVG), Fusion Antibodies (FAB), ValiRx (VAL), Genflow Biosciences (GENF), Oxford Cannabinoid Technologies (OCTP), Physiomics (PYC), and Nuformix (NFX). These companies are all part of the "biotechnology" industry.

BSF Enterprise vs.

Aptamer Group (LON:APTA) and BSF Enterprise (LON:BSFA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.

Aptamer Group has a beta of -0.42, suggesting that its share price is 142% less volatile than the S&P 500. Comparatively, BSF Enterprise has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.

1.5% of Aptamer Group shares are held by institutional investors. 31.7% of Aptamer Group shares are held by company insiders. Comparatively, 54.6% of BSF Enterprise shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, BSF Enterprise's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
Aptamer Group Neutral
BSF Enterprise Neutral

Aptamer Group's return on equity of -35.56% beat BSF Enterprise's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptamer GroupN/A -187.53% -44.96%
BSF Enterprise N/A -35.56%-20.49%

BSF Enterprise has lower revenue, but higher earnings than Aptamer Group. BSF Enterprise is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptamer Group£1.03M3.65-£7.01M-£0.08-10.06
BSF EnterpriseN/AN/A-£1.50M-£0.02-231.40

BSF Enterprise received 3 more outperform votes than Aptamer Group when rated by MarketBeat users.

CompanyUnderperformOutperform
Aptamer GroupN/AN/A
BSF EnterpriseOutperform Votes
3
75.00%
Underperform Votes
1
25.00%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptamer Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
BSF Enterprise
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

BSF Enterprise beats Aptamer Group on 7 of the 10 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BSFA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BSFA vs. The Competition

MetricBSF EnterpriseBiotechnology IndustryMedical SectorLON Exchange
Market Cap£4.78M£174.49M£5.15B£1.44B
Dividend YieldN/A3.43%36.92%11.86%
P/E Ratio-231.40248.99184.851,668.79
Price / SalesN/A15,531.552,412.69289,903.69
Price / Cash10.3011.2932.8832.85
Price / Book0.936.265.002.71
Net Income-£1.50M-£15.03M£104.44M£174.97M
7 Day Performance-7.44%0.71%0.62%0.98%
1 Month Performance-11.85%5.03%2.06%7.47%
1 Year Performance-65.40%3.79%5.34%8.42%

BSF Enterprise Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APTA
Aptamer Group
0 of 5 stars
GBX 0.81
-2.4%
N/A-93.0%£3.76M£1.03M-10.0637High Trading Volume
ROQ
Roquefort Therapeutics
0 of 5 stars
GBX 4.55
flat
N/AN/A£5.88M£637.00-455.009Gap Down
IXI
IXICO
0 of 5 stars
GBX 7.38
flat
N/A-62.2%£3.57M£6.67M-368.7589
EVG
Evgen Pharma
0 of 5 stars
GBX 0.80
flat
N/A-79.5%£3.42MN/A-80.0010
FAB
Fusion Antibodies
0 of 5 stars
GBX 3.50
+2.9%
N/A-90.9%£3.34M£1.58M-38.8948
VAL
ValiRx
0 of 5 stars
GBX 2.19
-28.3%
N/A-69.5%£2.89MN/A-72.878Gap Down
High Trading Volume
GENF
Genflow Biosciences
0 of 5 stars
GBX 2
+1.2%
N/A-38.9%£6.99MN/A-256.005Positive News
Gap Up
OCTP
Oxford Cannabinoid Technologies
0 of 5 stars
GBX 0.14
-6.0%
N/A-89.3%£1.54MN/A-53.107Gap Down
PYC
Physiomics
0 of 5 stars
GBX 1.12
-10.8%
N/A-60.4%£1.51M£900,707.00-13.8310Gap Up
NFX
Nuformix
0 of 5 stars
GBX 0.17
-6.5%
N/A-29.4%£1.42M£50,000.00-1.633Gap Down

Related Companies and Tools

This page (LON:BSFA) was last updated on 5/15/2024 by MarketBeat.com Staff

From Our Partners